Research programme: vectorised antibodies - VectorY
Latest Information Update: 03 Feb 2022
At a glance
- Originator VectorY
- Class Antibodies; Gene therapies
- Mechanism of Action Gene transference; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research CNS disorders; Musculoskeletal disorders
Most Recent Events
- 25 Jan 2022 VectorY and Wageningen University enter into strategic collaboration for the development of novel baculovirus-based AAV production technologies
- 11 Feb 2021 VectorY and Undisclosed company agree to co-develop vectorised antibodies for CNS disorders
- 11 Feb 2021 Early research in Musculoskeletal disorders in Netherlands(unspecified route)